In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Miles Houslay
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Miles Houslay

First Name:Miles
Last Name:Houslay
Advanced Degrees:PhD
Affiliation:University of Glasgow
Department:Biochemistry and Molecular Biology
Street Address 1:Wolfson Building
Street Address 2:University Avenue
Zip/Postal Code:G12 8QQ
Country/Territory:United Kingdom
Email Address:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 7 January 2006]
View all comments by Miles Houslay
Research Focus:
Bioinformatics/Statistics, Cell biology, Chemistry/pharmacology, Pharmacology, Proteomics, Signal transduction, Stem cells
Work Sector(s):
Web Sites:
Reasearcher Bio
Miles Houslay is Gardiner Professor of Biochemistry at the University of Glasgow, Scotland, UK. He obtained his first degree in Biochemistry at the University of Wales in Cardiff and then his PhD at the University of Cambridge and has held Faculty positions at the Universities of Cambridge and Manchester. He has been involved in cell signalling research since its inception. His current research interest is focussed on the role of phosphodiesterase-4 isoforms in underpinning cAMP compartmentalisation and cross-talk processes and potential for identifying novel therapeutic opportunities.
Top Papers

Hoffmann, R., Baillie, G.S., MacKenzie, S.J., Yarwood, S.J. & Houslay, M.D. (1999) EMBO J. 18, 893-903. The MAP kinase ERK2 inhibits the cyclic AMP specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.

McPhee, I., Yarwood, S.J., Huston, E., Scotland, G. Beard, M.B., Ross, A.H., Houslay, E.S. & Houslay, M.D. (1999) J. Biol. Chem. 274, 11796-11810. Association with the src family tyrosyl kinase lyn triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition.

MacKenzie, S. J., Baillie, G. S., McPhee, I., Bolger, G. B. & Houslay, M.D. (2000) J. Biol. Chem. 275, 16609–16617. ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: the involvement of C-terminal docking sites and N-terminal UCR regions.

Baillie, G.S., Huston, E., Scotland, G., Hodgkin, M., Gall, I., Peden, A.H., MacKenzie, C., Houslay, E.S., Currie, R., Pettitt, R., Walmsley, A.R., Wakelam, M.J.O., Warwicker, J. & Houslay, M.D. (2002) J. Biol. Chem. 277, 28298-28309. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid.

Perry, S.J.,* Baillie, G.S*., Kohout, T.A., McPhee, I., Magiera, M.M., Ang, K.L., Miller, W.E., McLean, A.J., Conti, M., Houslay, M.D. & Lefkowitz, R.J. (2002) Science 298, 834-836. ??arrestins regulate ?2-adrenoreceptor signaling by targeting cyclic AMP degradation.

Baillie, G.S, Sood, A., McPhee, I., Gall, I., Perry, S.J., Lefkowitz, R.J. & Houslay, M.D. (2003) Proc Natl Acad Sci 100, 940-945. ?-arrestin mediated PDE4 cAMP phosphodiesterase recruitment regulates ?2-adrenoceptor switching from Gs to Gi

Bolger, G.B., Peden, A.H., Steele, M.R., MacKenzie, C., McEwan, D.G., Wallace, D.A., Huston, E., Baillie, G.S. and Houslay, M.D. (2003) J. Biol. Chem. 278, 33351-33363. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.

Bolger, G.B., McCahill, A., Huston, E., Cheung, Y-F., McSorley, T., Baillie, G.S. and Houslay, M.D. (2003) J. Biol. Chem. 278, 49230-49238. The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with ?-arrestins.

Lynch, M.J., Baillie, G.S., Mohamed, A., Li, X., Maisonneuve, C., Klussmann, E., van Heeke, G. and Houslay, M.D. (2005) J. Biol. Chem 280, 33178-33189. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with ?-arrestin to control the PKA/AKAP79-mediated switching of the ?2-adrenoceptor to activation of ERK in HEK293 cells.

Millar, K., Pickard, B.J., Mackie, S., James, R., Christie, S., Buchanan, S.R., Malloy, M.P., Chubb, J.E., Huston, E., Baillie, G.S., Thomson, P.A., Hill, E.V., Brandon, N.J., Rain, J-C., Camargo, L.M., Whiting, P.J., Houslay, M.D., Blackwood, D.H.R., Muir, W.J. and Porteous, D.J. (2005) Science 310, 1187-1191. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signalling

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright